IKT
Inhibikase Therapeutics Inc

1,885
Mkt Cap
$206.15M
Volume
494,072.00
52W High
$3.32
52W Low
$1.33
PE Ratio
-2.98
IKT Fundamentals
Price
$1.65
Prev Close
$1.70
Open
$1.72
50D MA
$1.66
Beta
0.99
Avg. Volume
519,219.10
EPS (Annual)
-$1.16
P/B
1.74
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Inhibikase Therapeutics (NYSE:IKT) Earns Buy Rating from Analysts at Bank of America
Bank of America initiated coverage on shares of Inhibikase Therapeutics in a research report on Wednesday. They set a "buy" rating and a $6.00 price target on the stock...
MarketBeat·20d ago
News Placeholder
More News
News Placeholder
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) have been assigned a consensus rating of "Buy" from the five analysts that are presently covering the firm, Marketbeat reports...
MarketBeat·20d ago
News Placeholder
Inhibikase Therapeutics (NYSE:IKT) Trading Up 1.2% - What's Next?
Inhibikase Therapeutics (NYSE:IKT) Shares Up 1.2% - What's Next...
MarketBeat·24d ago
News Placeholder
Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 29.0%
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling...
MarketBeat·1mo ago
News Placeholder
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has earned a consensus recommendation of "Buy" from the five analysts that are presently covering the company, MarketBeat reports. One...
MarketBeat·1mo ago
News Placeholder
Inhibikase Therapeutics (NASDAQ:IKT) Raised to "Strong-Buy" at HC Wainwright
HC Wainwright raised shares of Inhibikase Therapeutics to a "strong-buy" rating in a research report on Friday...
MarketBeat·1mo ago
News Placeholder
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Sell at Wall Street Zen
Wall Street Zen raised Inhibikase Therapeutics to a "sell" rating in a report on Saturday...
MarketBeat·2mo ago
News Placeholder
Inhibikase Therapeutics (NYSE:IKT) Receives Buy Rating from HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of Inhibikase Therapeutics in a research note on Friday...
MarketBeat·2mo ago
News Placeholder
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Strong-Buy at Cantor Fitzgerald
Cantor Fitzgerald raised shares of Inhibikase Therapeutics to a "strong-buy" rating in a research note on Thursday...
MarketBeat·2mo ago
News Placeholder
Cantor Fitzgerald Initiates Coverage on Inhibikase Therapeutics (NYSE:IKT)
Cantor Fitzgerald initiated coverage on Inhibikase Therapeutics in a report on Thursday. They issued an "overweight" rating and a $4.00 price target on the stock...
MarketBeat·2mo ago
<
1
2
...
>

Latest IKT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.